Neuberger Berman Group LLC Galectin Therapeutics Inc Transaction History

Neuberger Berman Group LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$1.1 - $2.4 $2,200 - $4,800	-2,000 Reduced 14.69%	11,614 $24,000
Q1 2021 May 13, 2021	SELL	$1.96 - $2.57 $8,967 - $11,757	-4,575 Reduced 25.15%	13,614 $30,000
Q4 2020 Feb 10, 2021	SELL	$2.24 - $2.87 $124,835 - $159,945	-55,730 Reduced 75.39%	18,189 $41,000
Q3 2020 Nov 12, 2020	SELL	$2.53 - $3.64 $14,104 - $20,293	-5,575 Reduced 7.01%	73,919 $197,000
Q3 2019 Nov 13, 2019	SELL	$3.0 - $4.05 $9,000 - $12,150	-3,000 Reduced 3.64%	79,494 $292,000
Q3 2017 Nov 15, 2017	BUY	$1.67 - $2.3 $137,764 - $189,736	82,494	82,494 $177,000

9.69M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $73.7M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

Stay updated on Neuberger Berman Group LLC with notifications on news.